Retrospective Study
Copyright ©The Author(s) 2020.
World J Clin Cases. Aug 26, 2020; 8(16): 3458-3464
Published online Aug 26, 2020. doi: 10.12998/wjcc.v8.i16.3458
Table 1 Comparison of general data between the two groups, n (%)
GroupnMaleAge (yr)BMI (kg/m2)SmokingDrinking
Observation240168 (70.00)60.50 ± 9.2823.30 ± 5.44103 (42.92)63 (26.25)
Control15098 (65.33)59.22 ± 10.1122.83 ± 6.5056 (37.33)34 (22.67)
t/χ20.9271.2800.7691.1920.634
P value0.3360.2010.4420.2750.426
Table 2 Comparison of serum fibroblast growth factor-23 and miR-208b levels in the two groups
GroupnFGF-23 (ng/mL)Relative expression of miR-208b
Observation240210.20 ± 89.605.30 ± 1.22
Control150110.04 ± 32.292.90 ± 0.88
t13.16220.926
P value0.0000.000
Table 3 Comparison of serum fibroblast growth factor-23 and miR-208b in different subgroups of observation group
GroupnMan, n (%)Age (yr)FGF-23 (ng/mL)Relative expression of miR-208bLAD (mm)LVEDD (mm)LVESD (mm)LVEF (%)
Paroxysmal atrial fibrillation13498 (73.13)61.02 ± 10.11191.20 ± 65.594.88 ± 1.0234.03 ± 4.0250.03 ± 6.0332.10 ± 5.5853.30 ± 7.81
Persistent atrial fibrillation10670 (66.04)59.89 ± 9.92234.22 ± 70.055.83 ± 1.0038.81 ± 5.1149.81 ± 5.8232.01 ± 6.0252.83 ± 8.10
t1.4190.867-4.896-7.227-8.1120.2850.1200.455
P value0.2340.3870.0000.0000.0000.7760.9050.649
Table 4 Comparison of serum fibroblast growth factor-23 and miR-208b in patients with and without a major cardiovascular event
GroupnMan, n (%)Age (yr)FGF-23 (ng/mL)Relative expression of miR-208b
MACE5843 (74.14)61.19 ± 10.54243.30 ± 72.296.12 ± 1.12
Non-MACE182125 (68.68)62.28 ± 9.89199.65 ± 71.435.04 ± 1.07
t0.624-0.7194.0416.619
P value0.430.4730.0000.000